Century Lithium advances Angel Island project to support U.S. supply chain

Replenish Nutrients CEO Neil Wiens joined Steve Darling to announce its full-year and fourth quarter 2024 financial results, highlighting improved operational efficiency and profitability, alongside a business update that underscores the company’s strategic momentum heading into 2025. While full-year revenues and sales volumes were modestly down compared to 2023, Replenish Nutrients reported significant year-over-year improvement in gross profit margins, gross profit percentage, and adjusted EBITDA in the fourth quarter. These gains reflect enhanced cost efficiencies and growing market validation of the company’s proprietary regenerative fertilizer products. The company’s results were buoyed by strong repeat business from a loyal customer base and incremental sales to new clients, reinforcing the strength and efficacy of Replenish’s innovative product line. With full-scale production at the Beiseker facility expected to come online by mid-2025, Replenish anticipates a step-change in revenues, margin expansion, and cash flow generation. Wiens shared a significant milestone for its expansion roadmap, Replenish successfully closed $1.15 million in debt financing. These funds will be deployed immediately to complete critical upgrades at the company’s Beiseker granulation facility, enabling it to meet rising demand for sustainable fertilizer solutions ahead of the vital 2025 spring planting season. The Beiseker facility upgrades will bring production to 20,000–25,000 metric tonnes annually of granulated regenerative fertilizer. These enhancements are scheduled for completion by early Q2 2025, ensuring Replenish is optimally positioned for the high-volume spring application window—a key revenue driver for the business. Looking ahead, the company aims to scale to 2,000 tons per month and eventually fulfil increased demand represented by expanded purchase orders totaling 24,000 tons. To date, Replenish has already secured purchase orders for the first 6,000 metric tonnes of output at an average price of $575 per tonne, generating gross margins in the 25%–35% range, consistent with previous company guidance. Demand visibility remains high, and Replenish expects to sell out its full annual capacity, resulting in robust EBITDA and positive operating cash flow on a run-rate basis. #proactiveinvestors #replenishnutrientsholdingscorp #cse #erth #otc #vvivf #RegenerativeAgriculture #FertilizerInnovation #SustainableFarming #CropGrowth #NeilWiens #AgricultureNews #Farming2025 #ProactiveInvestors #SustainableSolutions

Ocean Power Technologies CEO Philipp Stratmann joined Steve Darling from Proactive to announce the shipment of a Merrows™-capable PowerBuoy® to support demonstrations for defense and security applications, including both surface and subsea monitoring. The deployment comes as part of a collaboration agreement signed last year with a major international defense contractor, targeting specific strategic regions. According to Stratmann, the simultaneous shipment of both a buoy and a vehicle in the same week underscores the company’s operational evolution and momentum. In addition to the buoy, Stratmann highlighted the shipment of a WAM-V® 22’, an autonomous surface vehicle engineered for offshore survey missions. The WAM-V® is equipped with 24/7 operational payload capacity, allowing it to operate for multiple days without needing to return to base. It recently completed a successful demonstration in which it conducted a three-day fully remote, continuous survey, while deploying a simulated payload. Stratmann emphasized that these deployments reflect OPT’s growing capabilities in supporting complex, autonomous maritime operations—especially in environments where persistent, unmanned monitoring is critical. #proactiveinvestors #oceanpowertechnologiesinc #nyseamerican #optt #PhillipStratmann, #USGovernmentContract, #OffshoreAutonomy, #MaritimeSecurity, #CommercialPlatforms, #GrowthStrategy, #BuoyBusiness, #VehicleBusiness, #InternationalExpansion, #ReadyToDeploy

Century Lithium CEO Bill Willoughby joined Steve Darling from Proactive to provide a comprehensive update on the company’s flagship Angel Island Lithium Project, a feasibility-stage development located in Nevada, one of the most resource-rich and mining-friendly jurisdictions in the United States. With growing urgency around the development of a domestic lithium supply chain, driven in part by the White House Executive Order to secure critical minerals essential to the U.S. economy and national security, Century Lithium believes it is strategically positioned to support this federal initiative. The Angel Island project is designed as a single-source mining and production operation for battery-grade lithium carbonate, a material vital for electric vehicles, renewable energy storage, and defense technologies. Dr. Willoughby noted that the company recently held a productive meeting with the Nevada State Office of the Bureau of Land Management to assess the permitting progress for the Angel Island project, in light of the federal directive. The meeting also addressed the current status of environmental studies, which are essential for progressing the project’s regulatory approvals. The next steps at the federal level include will include completion and final approval of all baseline environmental studies, preparation and submission of the Mine Plan of Operations, and then the BLM will determine the level of review required under the National Environmental Policy Act —either an Environmental Assessment or a more comprehensive Environmental Impact Statement. Angel Island is designed to be a fully integrated lithium operation, capable of producing an average of 34,000 tonnes per year of high-purity lithium carbonate over an estimated 40-year mine life. This end-to-end capability would make Angel Island a cornerstone contributor to the U.S. EV battery supply chain, reducing reliance on overseas processing and mitigating geopolitical risks associated with foreign supply. #proactiveinvestors #centurylithiumcorp #tsxv #lce #otcqx #cydvf #mining #oricaspecialtymining #CenturyLithium #BatteryMetals #USMining #EnergyTransition #EVs #MiningNews #LithiumProject #Tonopah #CriticalMinerals #PilotPlant #NEPA #BLM #CleanEnergy

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to announce a strategic decision to accelerate the clinical development of urcosimod, its lead candidate for Neuropathic Corneal Pain. CEO Gary Jacob shared the update in an interview with Proactive, highlighting the company's decision to terminate its ongoing Phase 2 trial early in order to access and analyze masked trial data that could inform the next stage of clinical advancement. The Phase 2 trial, being conducted at Tufts Medical Center in Boston, MA, was initially designed as a single-site study to evaluate the safety and efficacy of urcosimod in patients suffering from NCP—a debilitating and poorly understood ocular condition. To date, 17 patients have successfully completed the trial. All of them were diagnosed with chronic, long-term NCP and had failed multiple prior therapies, positioning this cohort as a challenging yet highly relevant population for evaluating urcosimod's potential. According to Jacob, the trial has attracted significant attention from NCP sufferers, reinforcing the high unmet need in this patient population. NCP is characterized by severe ocular pain, light sensitivity, and discomfort that can radiate to the face or head. Its exact etiology remains uncertain but is believed to involve nerve damage and persistent inflammation of the cornea. Currently, no approved therapies exist specifically for NCP, and most patients rely on off-label or palliative treatments with limited success. OKYO’s decision to close the trial early reflects a proactive strategic shift, allowing the company to refine its clinical development path and expedite next steps. The company is preparing to launch a multicenter trial, which will include multiple clinical sites and a broader patient population, enhancing the statistical robustness and generalizability of the data. As OKYO prepares for this next clinical phase, the company remains focused on its core mission of delivering innovative therapies for underserved ophthalmic conditions. The accelerated pathway for urcosimod underscores its potential to reshape the treatment landscape for neuropathic eye disorders. #proactiveinvestors #okyopharmalimited #nasdaq #okyo #Urcosimod #NeuropathicCornealPain #BiotechNews #ClinicalTrials #FDAapproval #Ophthalmology #DrugDevelopment #CompassionateUse #EyeHealth

Foresight Solar Fund Ltd's Toby Virno talked with Proactive's Stephen Gunnion about the company’s income performance, interest rate impacts, and strategic direction. Virno highlighted that since its IPO, the company has consistently paid a growing dividend and currently offers a yield of around 10% at prevailing share prices. "We've never missed a payment," he noted, reinforcing the company's income reliability. He addressed the macroeconomic outlook, including the Bank of England’s potential interest rate cuts, saying this environment could support growth by driving electricity demand. Importantly, he explained that Foresight Solar’s share price historically correlates with UK government bond yields, meaning falling rates may positively impact valuation. Foresight Solar has taken measures to narrow the discount to net asset value, including enhancing its dividend and deploying a proprietary development pipeline. Virno stated the pipeline includes nearly one gigawatt under development globally, which offers opportunities for capital growth through development, construction, and operations. The investment strategy stands on four pillars: income and growth, geographic diversification, operational excellence, and specialist management through Foresight Group. “Operational portfolio will continue to generate revenue … distributed to shareholders in the form of quarterly dividends,” Virno said. For more updates from energy and infrastructure leaders, visit Proactive's YouTube channel. Don't forget to like this video, subscribe, and enable notifications so you never miss a new release. #ForesightSolar #RenewableEnergy #DividendInvesting #InterestRates #GreenInfrastructure #TobyVirno #SolarEnergy #SustainableInvesting #EnergyStocks #IncomeGrowth

Cavendish research director James McCormack talked with Proactive about the UK North Sea oil and gas sector and the far-reaching consequences of the Energy Profits Levy (EPL). McCormack detailed how the EPL, originally introduced in 2022 as a temporary 25% measure, has since evolved into a 38% tax lasting through 2030, creating significant investment uncertainty. He explained, “The tax rate in the UK has gone from 40% in 2021 to 78% in its current state,” highlighting the shift as a major deterrent for continued exploration and production. The interview covers how this fiscal environment has accelerated production decline and increased the UK’s reliance on imports, leaving households and businesses exposed to international energy price volatility. Cavendish attributes declining output to reduced capital expenditure, citing record-low exploration in 2024 with just four wells drilled. McCormack also discussed ongoing government consultations, including those on Scope 3 emissions, fiscal regimes, and licensing policies. He noted the environmental trade-offs of increased imports, which can be up to four times more emissions-intensive than domestic production. He warned that further inaction or policy instability could see the North Sea become a "stranded opportunity," with early field closures, rising decommissioning liabilities, and a significant risk of skilled workforce loss. For more insights from industry voices, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #NorthSeaOil #UKEnergyPolicy #CavendishResearch #EnergyProfitsLevy #OilAndGasInvestment #EnergySecurity #UKGasCrisis #JamesMcCormack #Scope3Emissions #UKOilIndustry

HeLIX Exploration PLC CEO Bo Sears talked with Proactive's Stephen Gunnion about the completion of drilling at the Linda #1 well and its implications for the broader Rudyard field development. Sears described the recent helium gas shows as “incredible,” aligning closely with prior success at the Darwin #1 well. He emphasised that the structure is intact and the company is now in a position to focus on development drilling, stating, “We have removed a great deal of risk with regards to production of this field.” Sears also addressed the presence of oil shows in the reservoir, calling it “a good problem to have.” He noted multiple positive indicators, including fluorescence and strong mud cuttings, suggesting further exploration will follow. With casing and surface cementing completed, Helix is now awaiting a workover unit to begin testing the formations of interest. Sears explained this step is imminent, and the company expects to gather more data shortly. The consistent success across multiple wells at Rudyard suggests the field may offer expanding opportunities for development, with Sears noting, “We can punch a lot more holes in this entire field.” Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #HeLIXExploration #HeliumDrilling #Linda#1Well #RudyardField #BoSears #HeliumGas #OilShows #ExplorationUpdate #ResourceDevelopment #ProactiveInvestors #EnergySector

EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to announce the company has received a second progress payment from Procescir, a vertically integrated Mexican agriculture firm, for the purchase of a 120kW Radiant Energy Vacuum (REV™) machine. The machine will be used for commercial production of fruit and vegetable products in Mexico. Charleton revealed that Procescir plans to produce both private-label and branded snacks, as well as provide toll drying services to established and emerging brands. A significant boost to EnWave’s royalty stream is expected, as Procescir has signed a two-year toll drying agreement with a leading American healthy snack company, which will likely utilize the majority of the 120kW unit’s capacity. To stay ahead of demand, EnWave began manufacturing the 120kW REV™ machine in late 2024, ensuring timely delivery to Procescir by July 2025. In addition, EnWave will immediately begin building another large-scale REV™ system to meet anticipated future orders from its growing sales pipeline. #proactiveinvestors #enwavecorporation #tsxv #enw #DehydrationTech #VacuumMicrowave #RoyaltyBusinessModel #BluechipClients #FoodTech #BusinessNews #Investing #RadiantEnergyVacuum #Agritech #Procescir #DehydrationTechnology #FoodInnovation #SupplyAgreement #InvestmentNews #ProactiveInvestors

Tonix Pharmaceuticals Holdings has announced a groundbreaking collaborative research agreement with Makana Therapeutics, aiming to explore the potential of TNX-1500, Tonix’s anti-CD40L monoclonal antibody candidate, in advancing the field of xenotransplantation—the transplantation of animal-derived organs into human patients. In an interview with Steve Darling from Proactive, Tonix CEO Dr. Seth Lederman shared details of the preclinical partnership, which will evaluate TNX-1500 in combination with Makana’s proprietary human-compatible organs and cells, derived from genetically engineered pigs. The collaboration will initially focus on kidney, heart, and islet cell transplant models, with the broader objective of developing new treatment options for patients suffering from organ failure. The preclinical studies are designed to generate data to support a future Investigational New Drug (IND) application to the U.S. Food and Drug Administration, with the goal of enabling compassionate use of xenotransplantation therapies in patients who have no alternative treatment options. Makana’s approach centers around genetically engineered pigs that have been modified to lack swine leukocyte antigen (SLA), a key driver of immune rejection. These animals demonstrate enhanced compatibility with human biology and offer several potential advantages over competing technologies, including high fertility rates, increased litter sizes, and robust health profiles—key factors that support scalability and commercial viability in global markets. TNX-1500 is a next-generation anti-CD40L monoclonal antibody designed to modulate immune response while minimizing the risk of thrombosis—a common side effect associated with earlier anti-CD40L agents. The drug candidate holds promise in preventing organ transplant rejection, making it an ideal component of xenotransplantation protocols. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MPOXVaccine #Smallpox #TNX801 #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #ProactiveInvestors

KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) executive chairman Harry Anagnostaras-Adams talked with Proactive's Stephen Gunnion about significant developments regarding the company's Tulu Kapi gold project in Ethiopia. Anagnostaras-Adams confirmed the addition of BCM Group as both a syndicate member and the preferred mining contractor for the project. He explained, "BCM was part of the spearhead to make West African mining happen," highlighting the company’s strong background in mining across Africa. He noted that BCM’s commitment includes a contribution of US$23 million in pre-production costs, meaning KEFI's project development budget is now fully covered. He emphasised, "In essence, we're done," although some final procedural steps remain, such as certifying resettlement costs and finalising formal documentation. Anagnostaras-Adams also addressed KEFI’s strategic stance on its Saudi Arabian interests. With financial pressures alleviated by progress at Tulu Kapi, KEFI is no longer compelled to sell its Saudi assets and will focus on optimising its position in that market. Overall, the conversation highlighted that KEFI is transitioning from solving challenges to executing plans at Tulu Kapi, marking a critical inflection point for the company. Visit Proactive’s YouTube channel for more interviews and updates. Don’t forget to like the video, subscribe to the channel, and enable notifications to stay updated on future content. #KEFIGoldAndCopper #TuluKapi #GoldMining #MiningInvestment #EthiopiaMining #BCMGroup #MiningProjects #ResourceDevelopment #GoldExploration #ProactiveInvestors